Tumorigenesis and Neoplastic Progression FOXA 1 Promotes Tumor Progression in Prostate Cancer and Represents a Novel Hallmark of Castration-Resistant Prostate Cancer

Forkhead box protein A1 (FOXA1) modulates the transactivation of steroid hormone receptors and thus may influence tumor growth and hormone responsiveness in prostate cancer. We therefore investigated the correlation of FOXA1 expression with clinical parameters, prostate-specific antigen (PSA) relapse-free survival, and hormone receptor expression in a large cohort of prostate cancer patients at different disease stages. FOXA1 expression did not differ significantly between benign glands from the peripheral zone and primary peripheral zone prostate carcinomas. However, FOXA1 was overexpressed in metastases and particularly in castration-resistant cases, but was expressed at lower levels in both normal and neoplastic transitional zone tissues. FOXA1 levels correlated with higher pT stages and Gleason scores, as well as with androgen (AR) and estrogen receptor expression. Moreover, FOXA1 overexpression was associated with faster biochemical disease progression, which was pronounced in patients with low AR levels. Finally, siRNA-based knockdown of FOXA1 induced decreased cell proliferation and migration. Moreover, in vitro tumorigenicity was inducible by ARs only in the presence of FOXA1, substantiating a functional cooperation between FOXA1 and AR. In conclusion, FOXA1 expression is associated with tumor progression, dedifferentiation of prostate cancer cells, and poorer prognosis, as well as with cellular proliferation and migration and with AR signaling. These findings suggest FOXA1 overexpression as a novel mechanism inducing castration resistance in prostate cancer.

[1]  A. Passaniti,et al.  ErbB3 binding protein 1 represses metastasis-promoting gene anterior gradient protein 2 in prostate cancer. , 2010, Cancer research.

[2]  David E. Misek,et al.  The hepatocyte nuclear factor 3 alpha gene, HNF3alpha (FOXA1), on chromosome band 14q13 is amplified and overexpressed in esophageal and lung adenocarcinomas. , 2002, Cancer research.

[3]  S. Badve,et al.  High‐level expression of forkhead‐box protein A1 in metastatic prostate cancer , 2011, Histopathology.

[4]  R. Jove,et al.  Expression and role of Foxa proteins in prostate cancer , 2006, The Prostate.

[5]  Jonathan P. Katz,et al.  Inactivation of the winged helix transcription factor HNF3alpha affects glucose homeostasis and islet glucagon gene expression in vivo. , 1999, Genes & development.

[6]  Céline Lefebvre,et al.  From the Cover: Location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Christian Pilarsky,et al.  Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival , 2005, The Journal of pathology.

[8]  D. Beer,et al.  Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  Hyun Joo Lee,et al.  Hepatocyte nuclear factor-3 alpha (HNF-3alpha) negatively regulates androgen receptor transactivation in prostate cancer cells. , 2008, Biochemical and biophysical research communications.

[10]  Andreas Nitsche,et al.  Gene expression studies in prostate cancer tissue: which reference gene should be selected for normalization? , 2005, Journal of Molecular Medicine.

[11]  E. Lam,et al.  The emerging roles of forkhead box (Fox) proteins in cancer , 2007, Nature Reviews Cancer.

[12]  L. Tanoue.  Cancer Statistics, 2009 , 2010 .

[13]  R. Cardiff,et al.  Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. , 2008, The American journal of pathology.

[14]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[15]  G. Coetzee,et al.  Genomic Androgen Receptor-Occupied Regions with Different Functions, Defined by Histone Acetylation, Coregulators and Transcriptional Capacity , 2008, PloS one.

[16]  I. Leav,et al.  ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading. , 2010, Cancer cell.

[17]  C. Pilarsky,et al.  GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics , 2008, British Journal of Cancer.

[18]  J. Reis-Filho,et al.  Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis , 2007, Journal of Clinical Pathology.

[19]  G. Kristiansen,et al.  KPNA2 Expression Is an Independent Adverse Predictor of Biochemical Recurrence after Radical Prostatectomy , 2011, Clinical Cancer Research.

[20]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. , 2002, The Journal of urology.

[21]  Charles M Perou,et al.  FOXA1 Expression in Breast Cancer—Correlation with Luminal Subtype A and Survival , 2007, Clinical Cancer Research.

[22]  Liang Cheng,et al.  Estrogen receptor b 2 and b 5 are associated with poor prognosis in prostate cancer , and promote cancer cell migration and invasion , 2010 .

[23]  T. Golub,et al.  Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. , 2008, Journal of the National Cancer Institute.

[24]  G. Gu,et al.  Hedgehog pathway activity in the LADY prostate tumor model , 2007, Molecular Cancer.

[25]  P. Boyle,et al.  World Cancer Report 2008 , 2009 .

[26]  J. Darnell,et al.  HNF-3A, a hepatocyte-enriched transcription factor of novel structure is regulated transcriptionally. , 1990, Genes & development.

[27]  Frank R. Lin,et al.  Opening of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and GATA-4. , 2002, Molecular cell.

[28]  N. Ragavan,et al.  Gene expression profiling of the human prostate zones , 2006, BJU international.

[29]  M. Bosland.  The role of steroid hormones in prostate carcinogenesis. , 2000, Journal of the National Cancer Institute. Monographs.

[30]  G. Ball,et al.  Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance. , 2008, European journal of cancer.

[31]  David E. Misek,et al.  The Hepatocyte Nuclear Factor 3 α Gene, HNF3α (FOXA1), on Chromosome Band 14q13 Is Amplified and Overexpressed in Esophageal and Lung Adenocarcinomas , 2002 .

[32]  S. Burley,et al.  Co-crystal structure of the HNF-3/fork head DNA-recognition motif resembles histone H5 , 1993, Nature.

[33]  D Weigel,et al.  The fork head domain: A novel DNA binding motif of eukaryotic transcription factors? , 1990, Cell.

[34]  Z. Hall.  Cancer , 1906, The Hospital.

[35]  Carl W. Miller,et al.  FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancer , 2006, International journal of cancer.

[36]  Jorma Isola,et al.  In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.

[37]  Clifford A. Meyer,et al.  Chromosome-Wide Mapping of Estrogen Receptor Binding Reveals Long-Range Regulation Requiring the Forkhead Protein FoxA1 , 2005, Cell.

[38]  K. Kaestner,et al.  The Foxa family of transcription factors in development and metabolism , 2006, Cellular and Molecular Life Sciences CMLS.

[39]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[40]  Renjie Jin,et al.  The role of hepatocyte nuclear factor-3 alpha (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes. , 2003, Molecular endocrinology.

[41]  J. Gustafsson,et al.  Frequent Loss of Estrogen Receptor-β Expression in Prostate Cancer , 2001 .

[42]  M. Loda,et al.  Endothelial NOS, estrogen receptor beta, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer. , 2009, The Journal of clinical investigation.

[43]  I. Leav,et al.  Comparative Studies of the Estrogen Receptors β and α and the Androgen Receptor in Normal Human Prostate Glands, Dysplasia, and in Primary and Metastatic Carcinoma , 2001 .

[44]  T C Gasser,et al.  Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. , 1999, Cancer research.

[45]  Liang Cheng,et al.  Estrogen receptor β2 and β5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion , 2010, Endocrine-related cancer.

[46]  H. Bonkhoff,et al.  Differential expression of the estrogen receptor beta (ERβ) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma , 2003, The Prostate.

[47]  R. Caprioli,et al.  Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation , 2005, Development.

[48]  J. Mirosevich,et al.  Expression of Foxa transcription factors in the developing and adult murine prostate , 2005, The Prostate.

[49]  K. Harada,et al.  Analysis of differences in clinicopathological features between prostate cancers located in the transition and peripheral zones , 2006, International journal of urology : official journal of the Japanese Urological Association.

[50]  G. Kristiansen,et al.  Periostin is up-regulated in high grade and high stage prostate cancer , 2010, BMC Cancer.

[51]  O. Cussenot,et al.  Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. , 2001, Cancer research.

[52]  R. Vessella,et al.  Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.

[53]  J. Inoue,et al.  FoxA1 as a lineage-specific oncogene in luminal type breast cancer. , 2008, Biochemical and biophysical research communications.

[54]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.

[55]  R L Vessella,et al.  Advances in Brief Amplification and Overexpression of Androgen Receptor Gene in Hormone-Refractory Prostate Cancer 1 , 2001 .

[56]  M. Roncalli,et al.  Molecular disorders in transitional vs. peripheral zone prostate adenocarcinoma , 2001, International journal of cancer.

[57]  Holger Sültmann,et al.  The anterior gradient 2 (AGR2) gene is overexpressed in prostate cancer and may be useful as a urine sediment marker for prostate cancer detection , 2011, The Prostate.

[58]  J. Darnell,et al.  Hepatocyte nuclear factor 3 alpha belongs to a gene family in mammals that is homologous to the Drosophila homeotic gene fork head. , 1991, Genes & development.

[59]  G. Kristiansen,et al.  Tumorigenesis and Neoplastic Progression The Androgen-Regulated Calcium-Activated Nucleotidase 1 ( CANT 1 ) Is Commonly Overexpressed in Prostate Cancer and Is Tumor-Biologically Relevant in Vitro , 2011 .

[60]  Jeffrey A Whitsett,et al.  Compensatory Roles of Foxa1 and Foxa2 during Lung Morphogenesis* , 2005, Journal of Biological Chemistry.

[61]  G. Kristiansen,et al.  Profiling gastrin‐releasing peptide receptor in prostate tissues: Clinical implications and molecular correlates , 2012, The Prostate.

[62]  J. Gustafsson,et al.  Frequent loss of estrogen receptor-beta expression in prostate cancer. , 2001, Cancer research.

[63]  I. Leav,et al.  Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. , 2001, The American journal of pathology.

[64]  J E Darnell,et al.  Multiple hepatocyte-enriched nuclear factors function in the regulation of transthyretin and alpha 1-antitrypsin genes , 1989, Molecular and cellular biology.

[65]  J. Mirosevich,et al.  Foxa1 and Foxa2 Interact with the Androgen Receptor to Regulate Prostate and Epididymal Genes Differentially , 2005, Annals of the New York Academy of Sciences.